StockData
Xilio Therapeutics, Inc. logo

Xilio Therapeutics, Inc. (XLO) stock

XLONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 11/3080% below fair value
$7.54−0.16 (-2.08%)

Close on Nov 17, 2026Market cap $43.60MP/E –Yield –

Xilio Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Xilio Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $66.83M, up 54.7% year over year. For fiscal 2025 it was $56.04M, up 36.0% from the year before. The highest annual figure on record is $59.20M in fiscal 2022.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$56.04M+36.0%
FY2024Dec 31, 2024$41.21M-21.0%
FY2023Dec 31, 2023$52.14M-11.9%
FY2022Dec 31, 2022$59.20M+15.7%
FY2021Dec 31, 2021$51.19M+16.6%
FY2020Dec 31, 2020$43.91M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$14.56M-5.0%
Q1 FY2026Mar 31, 2026$19.83M+139.9%
Q4 FY2025Dec 31, 2025$18.12M+105.1%
Q3 FY2025Sep 30, 2025$14.32M+33.1%
Q2 FY2025Jun 30, 2025$15.33M+36.7%
Q1 FY2025Mar 31, 2025$8.27M-20.5%
Q4 FY2024Dec 31, 2024$8.84M-24.7%
Q3 FY2024Sep 30, 2024$10.76M-2.6%
Q2 FY2024Jun 30, 2024$11.22M-15.1%
Q1 FY2024Mar 31, 2024$10.40M-35.5%
Q4 FY2023Dec 31, 2023$11.74M-21.7%
Q3 FY2023Sep 30, 2023$11.05M-15.2%
Q2 FY2023Jun 30, 2023$13.22M-18.6%
Q1 FY2023Mar 31, 2023$16.13M+8.1%
Q4 FY2022Dec 31, 2022$15.00M+32.1%
Q3 FY2022Sep 30, 2022$13.04M+24.5%
Q2 FY2022Jun 30, 2022$16.25M-8.4%
Q1 FY2022Mar 31, 2022$14.92M+28.4%
Q4 FY2021Dec 31, 2021$11.35M-35.7%
Q3 FY2021Sep 30, 2021$10.47M-8.6%
Q2 FY2021Jun 30, 2021$17.75M–
Q1 FY2021Mar 31, 2021$11.62M–
Q4 FY2020Dec 31, 2020$17.67M–
Q3 FY2020Sep 30, 2020$11.46M–

More Xilio Therapeutics figures

See a number that looks wrong?